Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/21464
Title: Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand
Authors: Daniela K. Pirker-Krassnig
Gunther Wernsdorfer
Jeeraphat Sirichaisinthop
Chaiporn Rojanawatsirivet
Herwig Kollaritsch
Walther H. Wernsdorfer
Medizinische Universitat Wien
Mahidol University
Thailand Ministry of Public Health
Institute for Specific Prophylaxis and Tropical Medicine
Keywords: Medicine
Issue Date: 1-Dec-2004
Citation: Wiener Klinische Wochenschrift, Supplement. Vol.116, No.4 SUPPL. (2004), 47-52
Abstract: The occurrence of chloroquine resistance in Plasmodium vivax underlines the need for monitoring the drug response of this important malaria parasite and for the evaluation of alternative therapeutic agents. In-vitro methods facilitate these tasks. This investigation employed a recently developed in-vitro micro-technique and validated it for lumefantrine and desbutyl-benflumetol, a compound that was initially considered a metabolite of lumefantrine. The studies were conducted in 2001 at Mae Sot, a town situated in northwestern Thailand near the border to Myanmar. Parallel in-vitro tests with lumefantrine and desbutyl-benflumetol were carried out with 53 fresh isolates of P. vivax. For both compounds, the parasite showed a homogenous, log-normal inhibition pattern with nearly parallel log-probit regressions. The geometric mean drug concentrations effecting complete growth inhibition were 2361 nM for lumefantrine and 187 nM for desbutyl-benflumetol. With p = 3.264 × 10 -18 the difference was highly significant. The EC50 and EC90 values for lumefantrine, 17.6 nM and 448.5 nM, respectively, were much higher as compared to those determined for desbutyl-benflumetol, with 1.5 nM and 39.7 nM. This difference expressed itself in a highly significant Power Ratio (PR) of 11.0. The activity of desbutyl-benflumetol in P. vivax exceeds that of lumefantrine by one order of magnitude, suggesting a high, hitherto unexploited therapeutic potential of desbutyl-benflumetol.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=11244285196&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/21464
ISSN: 03005178
Appears in Collections:Scopus 2001-2005

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.